



Small, but heading for a big time

2013 Financial agenda

Paris, France, January 14, 2013 – **NANOBIOTIX (Euronext: NANO – ISIN: FR0011341205)**, a French company and nanomedicine pioneer developing NanoXray, a revolutionary therapeutic approach to local cancer treatment, today announces its indicative financial agenda for 2013.

Event	Date
Q4 2012/Full Year Sales	January 25 th , 2013
2012 Annual Results	April 29 th , 2013
Q1 2013	May 15 th , 2013
Q2 2013	July 12 th , 2013
2013 Half Year Results	August, 30 th , 2013
Q3 2013	November, 15 th , 2013

About NANOBIOTIX: www.NANOBIOTIX.com/fr

NANOBIOTIX, pioneer and leader in nanomedicine, has developed a revolutionary concept dedicated to the local treatment of cancer. NANOBIOTIX is focused on the development of NanoXray, a pipeline of patented products, which are based on the physical mechanism of action of the nanoparticles interacting with X-rays and maximizing radiation effect into tumor cells. NanoXray products enhance the efficacy of the radiotherapy in the tumor without increasing healthy tissues damages. NanoXray products can be used with existing standard radiation equipments available in almost every hospital worldwide.

NANOBIOTIX is a spin-off of the State University of New York (SUNY) at Buffalo that was incorporated in 2003 and has been primarily funded by leading European venture capital firms. The company has more than 30 employees and is based in Paris, France. NANOBIOTIX's objective is to enhance its leading position in the nanomedicine field on the main oncology markets. Its pipeline of universal products enable to target the major indications of cancers (breast cancer, prostate cancer, lung cancer...), leading to a potential market of several billion dollars. Thanks to the physical based mechanism of action of its nanoparticles, NANOBIOTIX deploys a unique business model with much lower risk than classic drug development, enabling a faster and less expensive time to market.

NANOBIOTIX is listed on the NYSE Euronext Paris regulated market (ISIN: FR0011341205, Euronext ticker: NANO, Bloomberg: NANO: FP)



Contacts

NANOBIOTIX

Laurent Levy

CEO and Co-founder

Tel: +33 (0)1 40 26 04 70

contact@NANOBIOTIX.com

NewCap.

Financial communication and Investor relations

Louis-Victor Delouvrier /

Emmanuel Huynh

Tel: +33 (0)1 44 71 98 53

lvdelouvrier@newcap.fr

Yucatan

Press Relations

Annie-Florence Loyer/

Nadège Le Lezec

Tel: +33 (0)1 53 63 27 27

afloyer@yucatan.tm.fr